Screener
Jazz Pharmaceuticals JAZZ Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Ordinary shares | — | — |
| Non-voting euro deferred shares | 0.1 | 0.1 |
| Capital redemption reserve | 0.5 | 0.5 |
| Additional paid-in capital | 4,243.5 | 4,240.5 |
| Accumulated other comprehensive loss | (651.0) | (568.6) |
| Retained earnings | 939.2 | 646.1 |
| Total shareholders’ equity | 4,532.3 | 4,318.6 |
| Total liabilities and shareholders’ equity | $11,859.6 | $11,659.3 |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's retained earnings?
- Jazz Pharmaceuticals (JAZZ) reported retained earnings of $939.2M in Q1 2026.
- How has Jazz Pharmaceuticals's retained earnings changed year-over-year?
- Jazz Pharmaceuticals's retained earnings decreased by 9.2% year-over-year, from $1.03B to $939.2M.
- What is the long-term trend for Jazz Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's retained earnings has grown at a -11.0% compound annual growth rate (CAGR), from $1.16B to $646.1M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Jazz Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude